

INN	Type	Application	Format	Species (C-domains)	Target A	Target B	Target C	Target D	No. of targets	Highest stage of development	Year
abagovomab	mab	Therapeutic	IgG	Mouse	idiotype of an				1	Phase 2/3	2006
abatacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD80/CD86				1	Approved	2004
abciximab	mab	Therapeutic	Unconfirmed		GP1IIB/IIIA				1	Approved	1998
abelacimab	mab	Therapeutic	IgG	Human	Factor XI				1	Phase 3	2018
ablituzumab	mab	Therapeutic	IgG	Human	Integrin alpha				1	Phase 2	2013
abrezekimab	mab	Therapeutic	Fab	Human	IL-13				1	Phase 1	2017
abrilumab	mab	Therapeutic	IgG	Human	Integrin alpha				1	Phase 2	2014
acapatamab	mab	Therapeutic	Tandem scFv-scFc	Human	PSMA	CD3			2	Phase 1	2020
acasunlimab	mab	Therapeutic	Bispecific IgG (type 6)	Human	PD-L1	4-1BB			2	Phase 2	2020
acazicolcept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD278/CD28				1	Phase 2	2020
acrixolimab	mab	Therapeutic	IgG	Human	PD-1				1	Phase 1	2022
actoxumab	mab	Therapeutic	IgG	Human	Clostridium d				1	Phase 3	2014
adalimumab	mab	Therapeutic	Unconfirmed		TNF alpha				1	Approved	2001
adebreliumab	mab	Therapeutic	IgG	Human	PD-L1				1	Phase 3	2019
adecatumumab	mab	Therapeutic	IgG	Human	EpCAM				1	Phase 2	2004
adintrevimab	mab	Therapeutic	IgG	Human	SARS-CoV-2				1	Phase 2/3	2021
aducanumab	mab	Therapeutic	IgG	Human	Amyloid beta				1	Approved	2013
afasevikumab	mab	Therapeutic	IgG	Human	IL-17				1	Phase 1	2015
afelimomab	mab	Therapeutic	Unconfirmed		TNF alpha				1	Phase 3	1998
afibercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	VEGF				1	Approved	2006
alacizumab	mab	Therapeutic	di-Fab'	Human	VEGF-R2				1	Phase 2	2007
alefacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD2				1	Approved	2000
alentuzumab	mab	Therapeutic	IgG	Human	CD52				1	Approved	2000
alirocumab	mab	Therapeutic	IgG	Human	PCSK9				1	Approved	2012
alnuctamab	mab	Therapeutic	Fab-IgG (type 1)	Human	BCMA	CD3			2	Phase 1	2020
alomfilimab	mab	Therapeutic	IgG	Human	CD278				1	Phase 1/2	2020
alsevalimab	mab	Therapeutic	IgG	Human	B7-H4				1	Phase 1	2019
altumomab	mab	Therapeutic	Unconfirmed		CEACAM5				1	Unknown	1998
amatuximab	mab	Therapeutic	IgG	Human	Mesothelin				1	Phase 2	2010
amivantamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	EGFR	HGFR			2	Approved	2019
amlitelimab	mab	Therapeutic	IgG	Human	OX40L				1	Phase 2	2020
amubarvimab	mab	Therapeutic	IgG	Human	SARS-CoV-2				1	Approved	2021
anatumomab	mab	Therapeutic	Unconfirmed		GP72	MHC Class 2			2	Unknown	2002
anbenitamab	mab	Therapeutic	Bispecific IgG (type 2)	Human	HER2	HER2			2	Phase 2	2020
andecaliximab	mab	Therapeutic	IgG	Human	MMP9				1	Phase 3	2016
anetumab	mab	Therapeutic	IgG	Human	Mesothelin				1	Phase 2	2019
anifrolumab	mab	Therapeutic	IgG	Human	Interferon rec				1	Approved	2013
anivovetmab	vetmab	Veterinary	IgG	Dog	VP2 (canine)				1	Unknown	2022
anrukinzumab	mab	Therapeutic	IgG	Human	IL-13				1	Phase 2	2007
anselamimab	mab	Therapeutic	IgG	Human	Amyloid				1	Phase 3	2022
ansuvimab	mab	Therapeutic	IgG	Human	Ebola virus				1	Approved	2020
anumigilimab	mab	Therapeutic	IgG	Human	CD114				1	Phase 1	2021
apamistamab	mab	Therapeutic	IgG	Mouse	CD45				1	Phase 3	2018
apitegromab	mab	Therapeutic	IgG	Human	Myostatin				1	Phase 3	2020
apolizumab	mab	Therapeutic	Unconfirmed		HLA-DR				1	Phase 2	2002
aprutumab	mab	Therapeutic	IgG	Human	FGFR2				1	Phase 1	2016
arcitumomab	mab	Imaging	IgG	Mouse	CEACAM5				1	Approved	1995
ascrinvacumab	mab	Therapeutic	IgG	Human	ALK1				1	Phase 2	2015
aselizumab	mab	Therapeutic	IgG	Human	CD62L				1	Phase 2	2003
asfotase	Other	Therapeutic	Fc fusion protein (type 1)	Human	hypophospha				1	Approved	2010
astegolimab	mab	Therapeutic	IgG	Human	IL-33R				1	Phase 2	2019
asunercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD95L				1	Phase 2	2015
atacicept	cept	Therapeutic	Fc fusion protein (type 1)	Human	BLYS/APRIL				1	Phase 2/3	2006
atezolizumab	mab	Therapeutic	IgG	Human	PD-L1				1	Approved	2014
atibucilimab	mab	Therapeutic	IgG	Human	CD14				1	Phase 2	2020
atidortoxumab	mab	Therapeutic	IgG	Human	Staphylococci				1	Phase 2	2017
atinumab	mab	Therapeutic	IgG	Human	NOGO-A				1	Phase 1	2010
atoltivimab	mab	Therapeutic	IgG	Human	Ebola virus				1	Approved	2018
atorolimumab	mab	Therapeutic	Unconfirmed		Rhesus D				1	Phase 1	1998
avdoralimab	mab	Therapeutic	IgG	Human	C5aR				1	Phase 2	2019
avelumab	mab	Therapeutic	IgG	Human	PD-L1				1	Approved	2015
avizakimab	mab	Therapeutic	IgG	Human	IL-21				1	Phase 1/2	2019
axatilimab	mab	Therapeutic	IgG	Human	CD115				1	Phase 2	2019
azintuxizumab	mab	Therapeutic	IgG	Human	SLAMF7				1	Phase 1	2016
bafisontamab	mab	Therapeutic	Fab-IgG (type 2)	Human	EGFR	HGFR			2	Phase 1/2	2021
balstilimab	mab	Therapeutic	IgG	Human	PD-1				1	Regulatory review	2019
baminercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	Lymphotoxin				1	Phase 2	2008
bamlanivimab	mab	Therapeutic	IgG	Human	SARS-CoV-2				1	EUA	2020
bapineuzumab	mab	Therapeutic	IgG	Human	Amyloid beta				1	Phase 3	2005
bapotulimab	mab	Therapeutic	IgG	Human	ILDR2				1	Phase 1	2020
barecetamab	mab	Therapeutic	IgG	Human	HER3				1	Phase 1	2020
barzolvolimab	mab	Therapeutic	IgG	Human	CD117				1	Phase 2	2021
basiliximab	mab	Therapeutic	Unconfirmed		CD25				1	Approved	1999
batiraxcept	cept	Therapeutic	Fc fusion protein (type 1)	Human	GA56				1	Phase 3	2020
batoclimab	mab	Therapeutic	IgG	Human	FcRn				1	Phase 3	2019
bavituximab	mab	Therapeutic	IgG	Human	Phosphatidyls				1	Phase 2/3	2006
bavunlimab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	CTLA-4	LAG-3			2	Phase 1	2021
bebtelovimab	mab	Therapeutic	IgG	Human	SARS-CoV-2				1	EUA	2022
bectumomab	mab	Imaging	Unconfirmed		CD22				1	Approved	1999
bedinvetmab	vetmab	Veterinary	IgG	Dog	NGF (canine)				1	Approved	2019
befovachimab	mab	Therapeutic	IgG	Human	Tissue factor				1	Phase 2	2019
begelomab	mab	Therapeutic	IgG	Mouse	DPP4				1	Regulatory review	2014
belantamab	mab	Therapeutic	IgG	Human	BCMA				1	Approved	2017
belatacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD80/CD86				1	Approved	2005
belimumab	mab	Therapeutic	IgG	Human	BLYs				1	Approved	2003
beludavimab	mab	Therapeutic	IgG	Human	SARS-CoV-2				1	Phase 1/2	2021
bemarituzumab	mab	Therapeutic	IgG	Human	FGFR2				1	Phase 3	2017

benralizumab	mab	Therapeutic	IgG	Human	IL-5	1	Approved	2009
bentracimab	mab	Therapeutic	Fab	Human	IL-5R	1	Phase 3	2020
benufutamab	mab	Therapeutic	IgG	Human	DR5	1	Phase 1/2	2019
bepranemab	mab	Therapeutic	IgG	Human	Tau	1	Phase 2	2019
berlimatoxumab	mab	Therapeutic	IgG	Human	Staphylococci	1	Phase 2	2017
bermekimab	mab	Therapeutic	IgG	Human	IL-1 alpha	1	Regulatory review	2018
bersanlimab	mab	Therapeutic	IgG	Human	CD54	1	Phase 2	2017
bertilimumab	mab	Therapeutic	Unconfirmed		Eotaxin-1	1	Phase 2	2003
besilesomab	mab	Imaging	Unconfirmed		NCA-95	1	Approved	2004
betifisolimab	mab	Therapeutic	IgG	Human	PD-L1	1	Phase 1	2022
bevacizumab	mab	Therapeutic	IgG	Human	VEGF	1	Approved	2002
bexmarilimab	mab	Therapeutic	IgG	Human	Cleaver-1	1	Phase 1/2	2019
bezlotoxumab	mab	Therapeutic	IgG	Human	Clostridium d	1	Approved	2012
biciromab	mab	Therapeutic	Unconfirmed		Fibrin	1	Phase 1/2	1991
bifikafusp	fusp	Therapeutic	scFv-protein fusion		Fibronectin	1	Phase 3	2017
bimagrumab	mab	Therapeutic	IgG	Human	ActRIIA ligand	1	Phase 2/3	2013
bimekizumab	mab	Therapeutic	IgG	Human	IL-17A/IL-17F	1	Approved	2013
bintrafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	PD-L1 TGF beta	2	Phase 3	2018
birtamimab	mab	Therapeutic	IgG	Human	Amyloid	1	Phase 3	2018
bivatuzumab	mab	Therapeutic	Unconfirmed		CD44v6	1	Phase 1	2002
bleselumab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2015
blinatumomab	mab	Therapeutic	Tandem scFv		CD19 CD3	2	Approved	2008
blisibimod	Other	Therapeutic	Fc fusion protein (type 1)	Human	BAFF	1	Phase 3	2012
blontuvetmab	vetmab	Veterinary	IgG	Dog	MS4A1	1	Unknown	2020
blosozumab	mab	Therapeutic	IgG	Human	Sclerostin	1	Phase 2	2011
bococizumab	mab	Therapeutic	IgG	Human	PCSK9	1	Phase 3	2013
botensilimab	mab	Therapeutic	IgG	Human	CTLA-4	1	Phase 2	2020
brazikumab	mab	Therapeutic	IgG	Human	IL-23	1	Phase 2/3	2016
brentuximab	mab	Therapeutic	IgG	Human	CD30	1	Approved	2010
briakinumab	mab	Therapeutic	IgG	Human	IL-12 beta	1	Regulatory review	2009
briobacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	BLys	1	Phase 1	2007
briquilimab	mab	Therapeutic	IgG	Human	CD117	1	Phase 1/2	2022
brodalumab	mab	Therapeutic	IgG	Human	IL-17RA	1	Approved	2011
brolocizumab	mab	Therapeutic	scFv		VEGF	1	Approved	2014
brontictuzumab	mab	Therapeutic	IgG	Human	Notch-1	1	Phase 1	2014
budigalimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2018
burfiralimab	mab	Therapeutic	IgG	Human	Vimentin	1	Phase 2	2022
buromsumab	mab	Therapeutic	IgG	Human	FGF23	1	Approved	2016
cabiralizumab	mab	Therapeutic	IgG	Human	CD115	1	Phase 2	2015
cadonilimab	mab	Therapeutic	IgG-scFv (type 1)	Human	PD-1 CTLA4	2	Regulatory review	2020
camidanlumab	mab	Therapeutic	IgG	Human	CD25	1	Phase 2	2017
camoteskimab	mab	Therapeutic	IgG	Human	IL-18	1	Phase 1	2022
camrelizumab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2016
canakinumab	mab	Therapeutic	IgG	Human	IL-1 beta	1	Approved	2007
cantuzumab	mab	Therapeutic	IgG	Human	MUC1	1	Phase 1	2011
caplacizumab	mab	Therapeutic	Tandem dAb (type 1)		von Willebrand von Willebrand	2	Approved	2011
capromab	mab	Imaging	Unconfirmed		PSMA	1	Phase 1	1998
carlumab	mab	Therapeutic	IgG	Human	CCL2	1	Phase 2	2010
carotuximab	mab	Therapeutic	IgG	Human	Endoglin	1	Phase 3	2015
casirivimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2020
catumaxomab	mab	Therapeutic	Unconfirmed		EpCAM CD3	2	Approved (withdra	2005
cedelizumab	mab	Therapeutic	Unconfirmed		CD4	1	Phase 2	1999
cemiplimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2018
cendakimab	mab	Therapeutic	IgG	Human	IL-13	1	Phase 3	2018
certuguzumab	mab	Therapeutic	IgG-protein fusion (type 2)	Human	CEACAM5 IL-2R	2	Phase 1	2015
certolizumab	mab	Therapeutic	Fab	Human	TNF alpha	1	Approved	2004
cetrelimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 3	2017
cetuximab	mab	Therapeutic	IgG	Human	EGFR	1	Approved	1999
cevostamab	mab	Therapeutic	Bispecific IgG (type 1)	Human	FcRL5 CD3	2	Phase 1	2019
cibisatamab	mab	Therapeutic	Fab-IgG (type 1)	Human	CEACAM5 CD3	2	Phase 1/2	2017
cifurtlimab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2022
cilgavimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2020
cinpanemab	mab	Therapeutic	IgG	Human	Synuclein alpl	1	Phase 2	2018
cinrebafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	HER2 4-1BB	2	Phase 2	2019
cirevetmab	vetmab	Veterinary	IgG	Dog	TGF beta (can	1	Unknown	2022
citatzumab	mab	Therapeutic	Fab-protein fusion (type 2)	Human	EpCAM Ribosomes	2	Phase 1	2008
cixutumumab	mab	Therapeutic	IgG	Human	IGF1R	1	Phase 2	2008
clazakizumab	mab	Therapeutic	IgG	Human	IL-6	1	Phase 3	2012
clenoliximab	mab	Therapeutic	Unconfirmed		CD4	1	Phase 2	1997
clervonafusp	fusp	Therapeutic	Fab-protein fusion (type 1)	Human	SLC29A2	1	Phase 1/2	2018
clesrovimab	mab	Therapeutic	IgG	Human	Respiratory sync	1	Phase 3	2022
clivatuzumab	mab	Therapeutic	IgG	Human	MUC1	1	Phase 3	2015
cobolimab	mab	Therapeutic	IgG	Human	TIM-3	1	Phase 2/3	2018
codrituzumab	mab	Therapeutic	IgG	Human	GPC3	1	Phase 2	2013
cofetuzumab	mab	Therapeutic	IgG	Human	PTK7	1	Phase 1	2017
coltuximab	mab	Therapeutic	IgG	Human	CD19	1	Phase 2	2013
conatumumab	mab	Therapeutic	IgG	Human	TRAIL-R2	1	Phase 2	2008
conbercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	VEGF	1	Phase 3	2011
concizumab	mab	Therapeutic	IgG	Human	Tissue factor	1	Phase 3	2012
coprelotamab	mab	Therapeutic	IgG	Human	HER2	1	Phase 3	2020
cosfroviximab	mab	Therapeutic	IgG	Human	Ebola virus	1	Approved	2016
cosibelimab	mab	Therapeutic	IgG	Human	PD-L1	1	Phase 3	2019
crefmirlimab	mab	Therapeutic	Minibody	Human	CD8A	1	Phase 2	2022
crenezumab	mab	Therapeutic	IgG	Human	Amyloid beta	1	Phase 3	2011
crexavibart	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Phase 2/3	2022
crizanlizumab	mab	Therapeutic	IgG	Human	CD62	1	Approved	2016
crotedumab	mab	Therapeutic	IgG	Human	GCGR	1	Phase 1	2015
crovalimab	mab	Therapeutic	IgG	Human	C5	1	Phase 3	2018
cudarolimab	mab	Therapeutic	IgG	Human	OX40	1	Phase 1	2019

cusatumab	mab	Therapeutic	IgG	Human	CD70	1	Phase 2	2017
dacetuzumab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2007
dacilizumab	mab	Therapeutic	IgG	Human	CD25	1	Approved (withdra	1997
dafsolimab	mab	Therapeutic	IgG	Mouse	CD3	1	Phase 3	2020
dalantcept	cept	Therapeutic	Fc fusion protein (type 1)	Human	BMP9/BMP10	1	Phase 2	2011
dalotuzumab	mab	Therapeutic	IgG	Human	IGF1R	1	Phase 2/3	2012
dalastrafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	CD73	2	Phase 1	2021
dapirolizumab	mab	Therapeutic	Fab	Human	CD40L	1	Phase 3	2013
daratumumab	mab	Therapeutic	IgG	Human	CD38	1	Approved	2009
datopotamab	mab	Therapeutic	IgG	Human	TROP-2	1	Phase 3	2020
davocetcept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD28/PD-L1/VE	1	Phase 1	2021
daxdilimab	mab	Therapeutic	IgG	Human	ILT7	1	Phase 2	2020
dectrekumab	mab	Therapeutic	IgG	Human	IL-13	1	Phase 2	2014
demcizumab	mab	Therapeutic	IgG	Human	DLL4	1	Phase 2	2012
demupitamab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 2	2019
denintuzumab	mab	Therapeutic	IgG	Human	CD19	1	Phase 2	2014
denosumab	mab	Therapeutic	IgG	Human	RANKL	1	Approved	2005
depatuxizumab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 3	2016
depemokimab	mab	Therapeutic	IgG	Human	IL-5	1	Phase 3	2020
derlotuximab	mab	Therapeutic	IgG	Human	DNA-associated	1	Phase 2	2015
detumomab	mab	Therapeutic	Unconfirmed		B-lymphoma	1	Phase 3	1998
dezamizumab	mab	Therapeutic	IgG	Human	Serum amyloid	1	Phase 2	2016
dilpacimab	mab	Therapeutic	Fv-IgG	Human	DLL4	2	Phase 2	2019
dinutuximab	mab	Therapeutic	IgG	Human	GD2	1	Approved	2013
diridavumab	mab	Therapeutic	IgG	Human	Influenza A H1N1	1	Phase 2	2014
disitamab	mab	Therapeutic	IgG	Human	HER2	1	Approved	2018
divozilimab	mab	Therapeutic	IgG	Human	CD20	1	Phase 3	2020
docaravimab	mab	Therapeutic	IgG	Mouse	Rabies virus	1	Approved	2019
domagrozumab	mab	Therapeutic	IgG	Human	Myostatin	1	Phase 2	2015
domvanalimab	mab	Therapeutic	IgG	Human	TIGIT	1	Phase 3	2020
donanemab	mab	Therapeutic	IgG	Human	Amyloid beta	1	Regulatory review	2018
dorlimomab	mab	Therapeutic	Unconfirmed		ricin	2	Unknown	1991
dostarlimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2018
dovanvetmab	vetmab	Veterinary	IgG	Cat	IL-31 (feline)	1	Unknown	2019
dresbuxelimab	mab	Therapeutic	IgG	Human	CD73	1	Phase 1	2021
drozitumab	mab	Therapeutic	IgG	Human	DR5	1	Phase 2	2010
dulaglutide	Other	Therapeutic	Fc fusion protein (type 1)	Human	GLP-1R	1	Approved	2010
duligotuzumab	mab	Therapeutic	IgG	Human	HER3	1	Phase 2	2013
dupilumab	mab	Therapeutic	IgG	Human	IL-4R	1	Approved	2012
durvalumab	mab	Therapeutic	IgG	Human	PD-L1	1	Approved	2014
dusigitumab	mab	Therapeutic	IgG	Human	IGF1/IGF2	1	Phase 2	2012
duvortuxizumab	mab	Therapeutic	Diabody-Fc (type 2)	Human	CD19	2	Phase 1	2016
ebdarokimab	mab	Therapeutic	IgG	Human	IL-12 beta	1	Phase 3	2020
ebulasakimab	mab	Therapeutic	IgG	Human	IL-13R alpha1	1	Phase 2	2021
eburonucimab	mab	Therapeutic	IgG	Human	PCSK9	1	Phase 3	2020
eccleralimab	mab	Therapeutic	Fab	Human	Thymic stroma	1	Phase 2	2021
ecromeximab	mab	Therapeutic	IgG	Human	GD3	1	Phase 2	2002
eculizumab	mab	Therapeutic	IgG	Human	C5	1	Approved	2002
edobacomab	mab	Therapeutic	Unconfirmed		Endotoxin	1	Phase 3	1998
edrecolomab	mab	Therapeutic	Unconfirmed		EpCAM	1	Approved (withdra	1995
efalizumab	mab	Therapeutic	IgG	Human	CD11a	1	Approved (withdra	2001
efanesoctocog	ef	Therapeutic	Fc fusion protein (type 7)	Human	Hemophilia	2	Unknown	2019
efapirnermin	ef	Therapeutic	Fc fusion protein (type 1)	Human	GITR	1	Unknown	2018
efavaleukin	ef	Therapeutic	Fc fusion protein (type 6)	Human	IL-2R	1	Unknown	2017
efemalenograstim	ef	Therapeutic	Fc fusion protein (type 1)	Human	CD114	1	Phase 3	2019
efdamrofusp	fusp	Therapeutic	Fc fusion protein (type 3)	Human	VEGF	2	Phase 2	2021
efepoetin	ef	Therapeutic	Fc fusion protein (type 1)	Human	EpoR	1	Unknown	2017
efgartigimod	ef	Therapeutic	Fc domain	Human	FcRn	1	Approved	2016
efgivanermin	ef	Therapeutic	Fc fusion protein (type 6)	Human	GITR	1	Unknown	2018
efineptakin	ef	Therapeutic	Fc fusion protein (type 1)	Human	IL-7R	1	Phase 2	2017
efinopegdutide	ef	Therapeutic	Protein conjugated Fc	Human	GLP-1R	1	Unknown	2018
efizonerimod	ef	Therapeutic	Fc fusion protein (type 6)	Human	TNFR	2	Unknown	2017
eflapeggrastim	ef	Therapeutic	Protein conjugated Fc	Human	GCSFR	1	Unknown	2014
eflenograstim	ef	Therapeutic	Fc fusion protein (type 1)	Human	GCSFR	1	Unknown	2017
eflepedocokin	ef	Therapeutic	Fc fusion protein (type 1)	Human	IL-22R	1	Unknown	2020
eflimrufusp	fusp	Therapeutic	Fc fusion protein (type 1)	Human	VEGF	1	Unknown	2020
efmarodocokin	ef	Therapeutic	Fc fusion protein (type 1)	Human	IL-22R	1	Unknown	2019
efmitemrant	ef	Therapeutic	Fc fusion protein (type 1)	Human	Myostatin	1	Phase 2	2019
efmorococog	ef	Therapeutic	Fc fusion protein (type 5)	Human	Hemophilia	1	Approved	2014
efocipegrtrutide	ef	Therapeutic	Protein conjugated Fc	Human	glucagon/GLP	1	Unknown	2020
efeglenatide	ef	Therapeutic	Small molecule conjugated Fc	Human	GLP-1R	1	Phase 2	2014
efegsomatropin	ef	Therapeutic	Protein conjugated Fc	Human	HGHR	1	Unknown	2016
efprezimid	ef	Therapeutic	Fc fusion protein (type 1)	Human	unknown	1	Unknown	2021
efrilacedase	ef	Therapeutic	Fc fusion protein (type 1)	Human	Angiotensin	1	Unknown	2020
efruxifermin	ef	Therapeutic	Fc fusion protein (type 6)	Human	FGFR	1	Unknown	2021
eftansomatropin	ef	Therapeutic	Fc fusion protein (type 1)	Human	HGHR	1	Phase 3	2017
eftilagimod	ef	Therapeutic	Fc fusion protein (type 1)	Human	HLA-DR	1	Phase 2	2016
eftozanermin	ef	Therapeutic	Fc fusion protein (type 1)	Human	DR4/DR5	1	Phase 1	2018
eftrenonacog	ef	Therapeutic	Fc fusion protein (type 5)	Human	Hemophilia	1	Approved	2006
efungumab	mab	Therapeutic	scFv		HSP90	1	Regulatory review	2006
efozitimod	ef	Therapeutic	Fc fusion protein (type 6)	Human	Neuropilin-2	1	Phase 3	2021
eldelumab	mab	Therapeutic	IgG	Human	CXCL10	1	Phase 2	2013
elezanumab	mab	Therapeutic	IgG	Human	Repulsive Gui	1	Phase 2	2016
elgemtumab	mab	Therapeutic	IgG	Human	HER3	1	Phase 1/2	2014
elipovimab	mab	Therapeutic	IgG	Human	HIV gp120	1	Phase 1	2018
elotuzumab	mab	Therapeutic	IgG	Human	SLAMF7	1	Approved	2008
elranatamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	BCMA	2	Phase 3	2021
elsilimomab	mab	Therapeutic	Unconfirmed		IL-6	1	Phase 2	2003
eluvixtamab	mab	Therapeutic	Tandem scFv		CD33	2	Phase 1	2020

emactuzumab	mab	Therapeutic	IgG	Human	CD115		1	Phase 1	2014
emapalumab	mab	Therapeutic	IgG	Human	Interferon ga		1	Approved	2016
emerfetamab	mab	Therapeutic	Tandem scFv-scFc	Human	CD33	CD3	2	Phase 1	2020
emfizatamab	mab	Therapeutic	IgG-scFv (type 2)	Human	CD19	CD3	4	Phase 1/2	2022
enibetuzumab	mab	Therapeutic	IgG	Human	HGFR		1	Phase 2	2014
emicizumab	mab	Therapeutic	Bispecific IgG (type 2)	Human	Factor Ixa	Factor X	2	Approved	2015
emirodatamab	mab	Therapeutic	Tandem scFv-scFc	Human	FLT3	CD3	2	Phase 1	2022
enapotamab	mab	Therapeutic	IgG	Human	AXL		1	Phase 1/2	2017
enavatuzumab	mab	Therapeutic	IgG	Human	TWEAK-R		1	Phase 1	2010
encelimab	mab	Therapeutic	IgG	Human	LAG-3		1	Phase 1	2019
enfortumab	mab	Therapeutic	IgG	Human	Nectin-4		1	Approved	2013
enibarcimab	mab	Therapeutic	IgG	Human	Adrenomedul		1	Phase 2/3	2020
enlimomab	mab	Therapeutic	Unconfirmed		CD54		1	Phase 2/3	1998
enoblituzumab	mab	Therapeutic	IgG	Human	B7-H3		1	Phase 2	2016
enokizumab	mab	Therapeutic	IgG	Human	IL-9		1	Phase 2	2010
enoticumab	mab	Therapeutic	IgG	Human	DLL4		1	Phase 1	2012
ensituximab	mab	Therapeutic	IgG	Human	MUC5AC		1	Phase 1/2	2010
ensomafusp	fusp	Therapeutic	IgG-protein fusion (type 3)	Human	CD19	4-1BB	2	Phase 1	2021
enzovivimab	mab	Therapeutic	IgG	Human	SARS-CoV-2		1	Phase 1	2021
envafolimab	mab	Therapeutic	dAb-Fc		PD-L1		1	Approved	2018
epcoritamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	CD20	CD3	2	Phase 3	2020
epitumomab	mab	Therapeutic	Unconfirmed		MUC1		1	Unknown	2007
epratuzumab	mab	Therapeutic	Unconfirmed		CD22		1	Phase 3	1999
eptinezumab	mab	Therapeutic	IgG	Human	CGRP		1	Approved	2016
eramkafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	CD20	IFN alpha rec	2	Phase 1	2020
erenumab	mab	Therapeutic	IgG	Human	CGRP		1	Approved	2016
erfonrilimab	mab	Therapeutic	Tandem dAb-Fc	Human	PD-L1	CTLA4	2	Phase 3	2020
erlizumab	mab	Therapeutic	F(ab') ₂	Human	CD18		1	Phase 2	2000
ertumaxomab	mab	Therapeutic	Unconfirmed		HER2	CD3	2	Phase 1/2	2005
etanercept	cept	Therapeutic	Unconfirmed		TNF alpha		1	Approved	1999
etaracizumab	mab	Therapeutic	IgG	Human	Integrin alph		1	Phase 2	2008
etesevimab	mab	Therapeutic	IgG	Human	SARS-CoV-2		1	EUA	2020
etevritamab	mab	Therapeutic	Tandem scFv		EGFR	CD3	2	Phase 1	2020
etigilimab	mab	Therapeutic	IgG	Human	TIGIT		1	Phase 1/2	2017
etokimab	mab	Therapeutic	IgG	Human	IL-33		1	Phase 2	2018
etrolizumab	mab	Therapeutic	IgG	Human	Integrin alph		1	Phase 3	2010
evinacumab	mab	Therapeutic	IgG	Human	Angiopoietin-		1	Approved	2014
evolocumab	mab	Therapeutic	IgG	Human	PCSK9		1	Approved	2012
evorpacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD47		1	Phase 2/3	2022
exbivirumab	mab	Therapeutic	IgG	Human	Hepatitis B vir		1	Phase 2	2004
exidavnemab	mab	Therapeutic	IgG	Human	Synuclein alpi		1	Phase 1	2021
ezabenlimab	mab	Therapeutic	IgG	Human	PD-1		1	Phase 2	2019
fanolesomab	mab	Imaging	Unconfirmed		CD15		1	Approved (withdra	2002
faralimomab	mab	Therapeutic	Unconfirmed		Interferon alp		1	Phase 1	1999
faricimab	mab	Therapeutic	Bispecific IgG (type 5)	Human	VEGF	Ang-2	2	Approved	2017
farletuzumab	mab	Therapeutic	IgG	Human	FOLR1		1	Phase 3	2008
fasinumab	mab	Therapeutic	IgG	Human	NGF		1	Phase 3	2012
favezelimab	mab	Therapeutic	IgG	Human	LAG-3		1	Phase 3	2020
fazpilodemab	mab	Therapeutic	Bispecific IgG (type 1)	Human	FGFR1	KLB	2	Phase 2	2022
feladilimab	mab	Therapeutic	IgG	Human	CD278		1	Phase 3	2019
felvizumab	mab	Therapeutic	Unconfirmed		Respiratory sy		1	Phase 3	1997
felzartamab	mab	Therapeutic	IgG	Human	CD38		1	Phase 3	2019
fezakinumab	mab	Therapeutic	IgG	Human	IL-22		1	Phase 2	2009
fianlimab	mab	Therapeutic	IgG	Human	LAG-3		1	Phase 3	2019
ficlatuzumab	mab	Therapeutic	IgG	Human	HGF		1	Phase 2	2011
fidasintamab	mab	Therapeutic	Bispecific IgG (type 1)	Human	PD-1	HER2	2	Phase 1	2021
figitumumab	mab	Therapeutic	IgG	Human	IGF1R		1	Phase 3	2008
finotonlimab	mab	Therapeutic	IgG	Human	PD-1		1	Phase 2/3	2020
firivumab	mab	Therapeutic	IgG	Human	Influenza A hi		1	Phase 2	2014
fiztasovimab	mab	Therapeutic	IgG	Human	CMV		1	Phase 2	2022
flavotumab	mab	Therapeutic	IgG	Human	GP75		1	Phase 1	2011
fletikumab	mab	Therapeutic	IgG	Human	IL-20		1	Phase 2	2013
flotetuzumab	mab	Therapeutic	Diabody		CD123	CD3	2	Phase 2	2017
fontolizumab	mab	Therapeutic	IgG	Human	Interferon ga		1	Phase 2	2002
foralumab	mab	Therapeutic	IgG	Human	CD3		1	Phase 1	2010
foravirumab	mab	Therapeutic	IgG	Human	Rabies virus		1	Phase 2	2008
fremanezumab	mab	Therapeutic	IgG	Human	CGRP		1	Approved	2016
fresolimumab	mab	Therapeutic	IgG	Human	TGF beta		1	Phase 2	2009
frexalimab	mab	Therapeutic	IgG	Human	CD40L		1	Phase 2	2022
frovocimab	mab	Therapeutic	IgG	Human	PCSK9		1	Phase 2	2018
frunevetmab	vetmab	Veterinary	IgG	Cat	NGF (feline)		1	Unknown	2016
fulranumab	mab	Therapeutic	IgG	Human	NGF		1	Phase 3	2010
futuximab	mab	Therapeutic	IgG	Human	EGFR		1	Phase 3	2012
galcanezumab	mab	Therapeutic	IgG	Human	CGRP		1	Approved	2015
galegenimab	mab	Therapeutic	Fab	Human	HtrA1		1	Phase 2	2021
galiximab	mab	Therapeutic	IgG	Human	CD80		1	Phase 2	2003
gancotamab	mab	Therapeutic	scFv		HER2		1	Phase 2/3	2018
ganitumab	mab	Therapeutic	IgG	Human	IGF1R		1	Phase 3	2010
gantenerumab	mab	Therapeutic	IgG	Human	Amyloid beta		1	Phase 3	2007
garadacimab	mab	Therapeutic	IgG	Human	Factor XIIa		1	Phase 3	2018
garetosmab	mab	Therapeutic	IgG	Human	Activin A		1	Phase 2	2018
garivulimab	mab	Therapeutic	IgG	Human	PD-L1		1	Phase 1/2	2020
gatipotuzumab	mab	Therapeutic	IgG	Human	MUC1		1	Phase 2	2017
gatralimab	mab	Therapeutic	IgG	Human	CD52		1	Phase 1	2019
gavilimomab	mab	Therapeutic	Unconfirmed		CD147		1	Phase 2/3	2000
gedivumab	mab	Therapeutic	IgG	Human	Influenza A hi		1	Phase 2	2017
gefurulimab	mab	Therapeutic	Tandem dAb (type 2)		C5	albumin	2	Phase 1	2022
gemtuzumab	mab	Therapeutic	IgG	Human	CD33		1	Approved	2000
geptanolimab	mab	Therapeutic	IgG	Human	PD-1		1	Regulatory review	2020

gevokizumab	mab	Therapeutic	IgG	Human	IL-1 beta	1	Phase 3	2010
giloralimab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2019
gilvetmab	vetmab	Veterinary	IgG	Dog	PDCCD1 (canin	1	Unknown	2016
gimsilumab	mab	Therapeutic	IgG	Human	GM-CSF	1	Phase 2	2017
ginisortamab	mab	Therapeutic	IgG	Human	GREM1	1	Phase 1/2	2021
girentuximab	mab	Therapeutic	IgG	Human	Carbonic anhy	1	Phase 2	2009
glembatumumab	mab	Therapeutic	IgG	Human	GPNMB	1	Phase 2	2009
glenzocimab	mab	Therapeutic	Fab	Human	GP6	1	Phase 2/3	2018
glofitamab	mab	Therapeutic	Fab-IgG (type 1)	Human	CD20 CD3	2	Regulatory review	2019
gofiiikcept	cept	Therapeutic	Fc fusion protein (type 4)	Human	IL-1B IL-1B	2	Phase 2/3	2020
golimumab	mab	Therapeutic	IgG	Human	TNF alpha	1	Approved	2004
golodcacimab	mab	Therapeutic	IgG	Human	LOX-1	1	Phase 2	2022
gontivimab	mab	Therapeutic	Triple dAb (type 1)		Respiratory s	1	Phase 2	2019
gosuranemab	mab	Therapeutic	IgG	Human	Tau	1	Phase 2	2018
gremubamab	mab	Therapeutic	IgG-scFv (type 4)	Human	Pseudomona: PcrV	2	Phase 2	2019
gresonitamab	mab	Therapeutic	Tandem scFv-scFc	Human	Claudin 18.2 CD3	2	Phase 1	2021
grisinlimab	mab	Therapeutic	IgG	Mouse	CD7	1	Phase 3	2020
gumokimab	mab	Therapeutic	IgG	Human	IL-17	1	Phase 2	2021
guselkumab	mab	Therapeutic	IgG	Human	IL-23	1	Approved	2013
ianalumab	mab	Therapeutic	IgG	Human	BAFF	1	Phase 3	2020
ibalizumab	mab	Therapeutic	IgG	Human	CD4	1	Approved	2007
ibrutumomab	mab	Therapeutic	Unconfirmed		CD20	1	Approved	2002
icrucumab	mab	Therapeutic	IgG	Human	VEGF-R1	1	Phase 2	2010
idactamab	mab	Therapeutic	IgG	Human	ASCT2	1	Phase 1	2020
idarucizumab	mab	Therapeutic	Fab	Human	Dabigatran	1	Approved	2016
ieramilimab	mab	Therapeutic	IgG	Human	LAG-3	1	Phase 2	2018
ifabotuzumab	mab	Therapeutic	IgG	Human	EPHA3	1	Phase 1	2016
ifinatamab	mab	Therapeutic	IgG	Human	B7-H3	1	Phase 2	2022
igovomab	mab	Imaging	Unconfirmed		CA125	1	Approved (withdra	2002
iladatuzumab	mab	Therapeutic	IgG	Human	CD79b	1	Phase 1	2017
imalumab	mab	Therapeutic	IgG	Human	MIF	1	Phase 2	2014
imaprelimab	mab	Therapeutic	IgG	Human	MCAM	1	Phase 1	2017
imciromab	mab	Imaging	Unconfirmed		Cardiac myos	1	Approved (withdra	1991
imdevimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2020
imgatuzumab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 2	2012
imsidolimab	mab	Therapeutic	IgG	Human	IL-36R	1	Phase 3	2020
imvotamab	mab	Therapeutic	IgM with J chain fusion	Human	CD20 CD3 None	3	Phase 1	2022
inbakicept	cept	Therapeutic	Fc fusion protein (type 1)	Human	IL-15	1	Regulatory review	2018
inlacumab	mab	Therapeutic	IgG	Human	CD62	1	Phase 3	2011
indatuximab	mab	Therapeutic	IgG	Human	CD138	1	Phase 1/2	2011
indusatumab	mab	Therapeutic	IgG	Human	Guanylyl cycli	1	Phase 2	2014
inebilizumab	mab	Therapeutic	IgG	Human	CD19	1	Approved	2015
inezetamab	mab	Therapeutic	IgG-scFv (type 1)	Human	Mesothelin CD4	2	Phase 1	2022
infiximab	mab	Therapeutic	Unconfirmed		TNF alpha	1	Approved	1997
inolimomab	mab	Therapeutic	Unconfirmed		CD25	1	Regulatory review	1998
inotuzumab	mab	Therapeutic	IgG	Human	CD22	1	Approved	2004
intetumumab	mab	Therapeutic	IgG	Human	Integrin alphaz	1	Phase 2	2009
ipafricept	cept	Therapeutic	Fc fusion protein (type 1)	Human	WNT ligand	1	Phase 1	2013
iparomilimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2021
ipilimumab	mab	Therapeutic	IgG	Human	CTLA-4	1	Approved	2005
iratumumab	mab	Therapeutic	IgG	Human	CD30	1	Phase 2	2005
isatuximab	mab	Therapeutic	IgG	Human	CD38	1	Approved	2014
iscalimab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2017
isecaromab	mab	Therapeutic	Tandem dAb (type 2)		ADAMTS-5 albumin	2	Phase 1	2019
ispectamab	mab	Therapeutic	IgG	Human	BCMA	1	Phase 1	2022
istiratumab	mab	Therapeutic	IgG-scFv (type 1)	Human	IGF1R HER3	2	Phase 2	2017
itepekimab	mab	Therapeutic	IgG	Human	IL-33	1	Phase 3	2019
itolizumab	mab	Therapeutic	IgG	Human	CD6	1	Approved	2010
ivicentamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	CD37 CD37	2	Phase 1/2	2021
ivonescimab	mab	Therapeutic	IgG-scFv (type 1)	Human	PD-1 VEGF	2	Phase 3	2021
ivuxolimab	mab	Therapeutic	IgG	Human	OX40	1	Phase 3	2019
ixekizumab	mab	Therapeutic	IgG	Human	IL-17A	1	Approved	2011
izalontamab	mab	Therapeutic	IgG-scFv (type 1)	Human	EGFR HER2	2	Phase 2/3	2022
izenivetmab	vetmab	Veterinary	IgG	Dog	NGF (canine)	1	Unknown	2022
izuralimab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	PD-1 ICOS	2	Phase 1	2020
keliximab	mab	Therapeutic	Unconfirmed		CD4	1	Phase 2	1999
labetuzumab	mab	Therapeutic	IgG	Human	CEACAM5	1	Phase 1/2	2001
lacnotuzumab	mab	Therapeutic	IgG	Human	M-CSF	1	Phase 2	2016
laceutamab	mab	Therapeutic	IgG	Human	KIR3DL2	1	Phase 2	2019
ladiratuzumab	mab	Therapeutic	IgG	Human	LIV-1	1	Phase 2	2017
lampalizumab	mab	Therapeutic	Fab	Human	Factor D	1	Phase 3	2012
lanadelumab	mab	Therapeutic	IgG	Human	Plasma kallikr	1	Approved	2015
landogrozumab	mab	Therapeutic	IgG	Human	Myostatin	1	Phase 2	2015
laprituximab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 1	2015
larcaviximab	mab	Therapeutic	IgG	Human	Ebola virus	1	Approved	2016
latikafusp	fusp	Therapeutic	IgG-protein fusion (type 2)	Human	PD-1 IL-21R	2	Phase 1	2022
latozinemab	mab	Therapeutic	IgG	Human	Sortilin	1	Phase 3	2020
lebrikizumab	mab	Therapeutic	IgG	Human	IL-13	1	Phase 3	2009
lecanemab	mab	Therapeutic	IgG	Human	Amyloid beta	1	Regulatory review	2019
lemalesomab	mab	Therapeutic	IgG	Mouse	NCA-90	1	Phase 1	2002
lemzoparlimab	mab	Therapeutic	IgG	Human	CD47	1	Phase 2	2020
lenercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	TNF alpha	1	Phase 3	1994
lenvervimab	mab	Therapeutic	IgG	Human	Hepatitis B vii	1	Phase 2/3	2017
lenzilumab	mab	Therapeutic	IgG	Human	GM-CSF	1	Phase 3	2014
lepunafusp	fusp	Therapeutic	Fab-protein fusion (type 1)	Human	Transferrin re	1	Phase 1/2	2021
lerdelimumab	mab	Therapeutic	IgG	Human	TGF beta	1	Phase 3	2002
leronlimab	mab	Therapeutic	IgG	Human	CCR5	1	Regulatory review	2017
lesabelimab	mab	Therapeutic	IgG	Human	PD-L1	1	Phase 1	2022
lesofavumab	mab	Therapeutic	IgG	Human	Influenza B h	1	Phase 1	2017

letaplimab	mab	Therapeutic	IgG	Human	CD47		1	Phase 1/2	2020
letolizumab	mab	Therapeutic	dAb-Fc	Human	CD40L		1	Phase 1/2	2016
levilimab	mab	Therapeutic	IgG	Human	IL-6R		1	Approved	2018
lexatumumab	mab	Therapeutic	IgG	Human	TRAIL-R2		1	Phase 1	2006
libivirumab	mab	Therapeutic	IgG	Human	Hepatitis B vir		1	Phase 2	2004
licamnilimab	mab	Therapeutic	scFv		TNF alpha		1	Phase 2	2020
lifastuzumab	mab	Therapeutic	IgG	Human	NaPI2b		1	Phase 2	2013
ligelizumab	mab	Therapeutic	IgG	Human	IgE		1	Phase 3	2012
ligufalimab	mab	Therapeutic	IgG	Human	CD47		1	Phase 2	2021
lilotomab	mab	Therapeutic	IgG	Mouse	CD37		1	Phase 2	2014
lintuzumab	mab	Therapeutic	IgG	Human	CD33		1	Phase 2	2019
linvoseltamab	mab	Therapeutic	Bispecific IgG (type 3)	Human	BCMA	CD3	2	Phase 2	2022
lirentelimab	mab	Therapeutic	IgG	Human	Siglec-8		1	Phase 3	2020
lirilumab	mab	Therapeutic	IgG	Human	KIRD2		1	Phase 2	2012
litifilimab	mab	Therapeutic	IgG	Human	CLEC4C		1	Phase 3	2022
livmoniplimab	mab	Therapeutic	IgG	Human	LRRC32		1	Phase 1	2021
lodapolimab	mab	Therapeutic	IgG	Human	PD-L1		1	Phase 1	2019
lodelcizumab	mab	Therapeutic	IgG	Human	PCSK9		1	Phase 1	2012
lokivetmab	vetmab	Veterinary	IgG	Dog	IL-31		1	Approved	2014
lomtegovimab	mab	Therapeutic	IgG	Human	SARS-CoV-2		1	Phase 2/3	2021
loncastuximab	mab	Therapeutic	IgG	Human	CD19		1	Approved	2017
lonigutamab	mab	Therapeutic	IgG	Human	IGF1R		1	Phase 1/2	2020
lorigerlimab	mab	Therapeutic	Diabody-Fc (type 1)	Human	PD-1	CTLA4	2	Phase 1	2021
lorukafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	GD2	IL-2R	2	Phase 2	2018
lorvotuzumab	mab	Therapeutic	IgG	Human	CD56		1	Phase 2	2010
losatuxizumab	mab	Therapeutic	IgG	Human	EGFR		1	Phase 1	2016
lucatumumab	mab	Therapeutic	IgG	Human	CD40		1	Phase 2	2007
lulizumab	mab	Therapeutic	dAb		CD28		1	Phase 2	2014
lumiliximab	mab	Therapeutic	Unconfirmed		CD23		1	Phase 2/3	2004
lumretuzumab	mab	Therapeutic	IgG	Human	HER3		1	Phase 1/2	2014
lupartumab	mab	Therapeutic	IgG	Human	LYPD3		1	Phase 1	2016
luspatercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	ActRIIA ligand		1	Approved	2013
lusvertikimab	mab	Therapeutic	IgG	Human	IL-7R		1	Phase 2	2020
lutikizumab	mab	Therapeutic	Fv-IgG	Human	IL-1 alpha	IL-1 beta	2	Phase 2	2016
luveltamab	mab	Therapeutic	IgG	Human	FOLR1		1	Phase 1	2022
maftivimab	mab	Therapeutic	IgG	Human	Ebola virus		1	Approved	2018
magrolimab	mab	Therapeutic	IgG	Human	CD47		1	Phase 3	2018
manelimab	mab	Therapeutic	IgG	Human	PD-L1		1	Phase 1	2019
manfidokimab	mab	Therapeutic	IgG	Human	IL-4R		1	Phase 2	2021
mapatumumab	mab	Therapeutic	Unconfirmed		TRAIL-R1		1	Phase 2	2005
margetuximab	mab	Therapeutic	IgG	Human	HER2		1	Approved	2013
marstacimab	mab	Therapeutic	IgG	Human	Tissue factor		1	Phase 3	2018
masavibart	bart	Therapeutic	IgG	Human	SARS-CoV-2		1	Unknown	2022
maslimomab	mab	Therapeutic	Unconfirmed		TCR		1	Phase 1	1991
matuzumab	mab	Therapeutic	Unconfirmed		EGFR		1	Phase 2	2003
mavrilimumab	mab	Therapeutic	IgG	Human	CD116		1	Phase 2/3	2009
mazorelvimab	mab	Therapeutic	IgG	Human	Rabies virus		1	Phase 3	2021
mecbotamab	mab	Therapeutic	IgG	Human	AXL		1	Phase 2	2022
melredableukin	Other	Therapeutic	IgG-protein fusion (type 1)	Human	IL-2R	IL-2R	2	Phase 2	2021
melrilimab	mab	Therapeutic	IgG	Human	IL-33R		1	Phase 2	2020
mepolizumab	mab	Therapeutic	IgG	Human	IL-5		1	Approved	1999
metelimumab	mab	Therapeutic	IgG	Human	TGF beta		1	Phase 2	2003
mezagitamab	mab	Therapeutic	IgG	Human	CD38		1	Phase 2	2019
mibavademab	mab	Therapeutic	IgG	Human	LEPR		1	Phase 2	2020
milatuzumab	mab	Therapeutic	IgG	Human	CD74		1	Phase 1/2	2007
minretumomab	mab	Therapeutic	Unconfirmed		Tag-72		1	Phase 1	1998
mipasetamab	mab	Therapeutic	IgG	Human	AXL		1	Phase 1	2020
miptenalimab	mab	Therapeutic	IgG	Human	LAG-3		1	Phase 2	2019
mirikizumab	mab	Therapeutic	IgG	Human	IL-23		1	Phase 3	2017
miromavimab	mab	Therapeutic	IgG	Mouse	Rabies virus		1	Approved	2019
mirvetuximab	mab	Therapeutic	IgG	Human	FOLR1		1	Regulatory review	2015
mirzotamab	mab	Therapeutic	IgG	Human	B7-H3		1	Phase 1	2019
mitazalimab	mab	Therapeutic	IgG	Human	CD40		1	Phase 2	2018
mitumomab	mab	Therapeutic	Unconfirmed		GD3		1	Phase 3	1999
modakafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	CD38	IFN alpha rec	2	Phase 1/2	2019
modotuximab	mab	Therapeutic	IgG	Human	EGFR		1	Phase 3	2013
mogamulizumab	mab	Therapeutic	IgG	Human	CCR4		1	Approved	2010
monalizumab	mab	Therapeutic	IgG	Human	CD159a		1	Phase 3	2015
morolimumab	mab	Therapeutic	Unconfirmed		Rhesus D		1	Phase 1	1998
mosunetuzumab	mab	Therapeutic	Bispecific IgG (type 1)	Human	CD20	CD3	2	Regulatory review	2017
motavizumab	mab	Therapeutic	IgG	Human	Respiratory sy		1	Regulatory review	2006
moxetumomab	mab	Therapeutic	Fv-protein fusion		CD22	LRP1	2	Approved	2009
mupadolimab	mab	Therapeutic	IgG	Human	CD73		1	Phase 3	2021
murlentamab	mab	Therapeutic	IgG	Human	Mullerian inh		1	Phase 2	2018
muromonab	Other	Therapeutic	Unconfirmed		CD3		1	Approved (withdra	1988
naicolomab	mab	Therapeutic	Unconfirmed		Colorectal tur MHC Class 2		2	Unknown	1998
nadecnemab	mab	Therapeutic	IgG	Human	GFRA3		1	Phase 2	2020
nadunolimab	mab	Therapeutic	IgG	Human	IL-1R accesso		1	Phase 2/3	2019
namilumab	mab	Therapeutic	IgG	Human	GM-CSF		1	Phase 2	2010
naptumomab	mab	Therapeutic	Fab-protein fusion (type 1)	Mouse	TPBG		1	Phase 2/3	2006
naratuximab	mab	Therapeutic	IgG	Human	CD37		1	Phase 2	2015
narnatumab	mab	Therapeutic	IgG	Human	RON8		1	Phase 1	2011
narsoplimab	mab	Therapeutic	IgG	Human	MASP-2		1	Regulatory review	2020
natalizumab	mab	Therapeutic	IgG	Human	Integrin alph		1	Approved	1998
navicixizumab	mab	Therapeutic	Bispecific IgG (type 2)	Human	DLL4	VEGF	2	Phase 3	2015
navivumab	mab	Therapeutic	IgG	Human	Influenza A vi		1	Phase 2	2015
naxitamab	mab	Therapeutic	IgG	Human	GD2		1	Approved	2018
nebacumab	mab	Therapeutic	Unconfirmed		Endotoxin		1	Approved (withdra	1991
neцитumab	mab	Therapeutic	IgG	Human	EGFR		1	Approved	2008

nemolizumab	mab	Therapeutic	IgG	Human	IL-31R alpha	1	Approved	2014
nepuvibart	bart	Therapeutic	IgG	Human	SARS-CoV-2	1	Unknown	2022
nerelimomab	mab	Therapeutic	Unconfirmed		TNF alpha	1	Phase 3	1999
nesvacumab	mab	Therapeutic	IgG	Human	Ang-2	1	Phase 2	2012
netakimab	mab	Therapeutic	IgG	Human	IL-17	1	Approved	2017
nimacimab	mab	Therapeutic	IgG	Human	Cannabinoid	1	Phase 2	2018
nimotuzumab	mab	Therapeutic	IgG	Human	EGFR	1	Approved	2005
nipocalimab	mab	Therapeutic	IgG	Human	FcRn	1	Phase 2/3	2019
nirsevimab	mab	Therapeutic	IgG	Human	Respiratory syncytial virus	1	Regulatory review	2018
nivatrotamab	mab	Therapeutic	IgG-scFv (type 3)	Human	GD2	2	Phase 1/2	2020
nivolumab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2014
nofazinlimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 3	2021
nofetumomab	mab	Therapeutic	Unconfirmed		GP40	1	Unknown	1999
nurulimab	mab	Therapeutic	IgG	Human	CTLA-4	1	Phase 2	2019
obexelimab	mab	Therapeutic	IgG	Human	CD19	1	Phase 2	2018
oblitoxaximab	mab	Therapeutic	IgG	Human	Bacillus anthracis	1	Approved	2015
obinutuzumab	mab	Therapeutic	IgG	Human	CD20	1	Approved	2013
obrindatamab	mab	Therapeutic	Diabody-Fc (type 2)	Human	B7-H3	2	Phase 1	2020
ocaratumzumab	mab	Therapeutic	IgG	Human	CD20	1	Phase 1/2	2012
ociperlimab	mab	Therapeutic	IgG	Human	TIGIT	1	Phase 3	2020
ocrelizumab	mab	Therapeutic	IgG	Human	CD20	1	Approved	2006
odesivimab	mab	Therapeutic	IgG	Human	Ebola virus	1	Approved	2019
odronextamab	mab	Therapeutic	Bispecific IgG (type 3)	Human	CD20	2	Phase 2	2019
odulimomab	mab	Therapeutic	Unconfirmed		CD11a	1	Phase 3	1999
ofatumumab	mab	Therapeutic	IgG	Human	CD20	1	Approved	2005
ogalvibart	bart	Therapeutic	IgG	Human	SARS-CoV-2	1	Phase 2/3	2022
olamkicept	cept	Therapeutic	Fc fusion protein (type 1)	Human	IL-6	1	Phase 2	2016
olaratumab	mab	Therapeutic	IgG	Human	PDGFR alpha	1	Approved (withdrawn)	2010
oleclumab	mab	Therapeutic	IgG	Human	CD73	1	Phase 3	2016
olendalizumab	mab	Therapeutic	IgG	Human	C5	1	Phase 2	2016
olinvacimab	mab	Therapeutic	IgG	Human	VEGF-R2	1	Phase 2	2018
olokizumab	mab	Therapeutic	IgG	Human	IL-6	1	Approved	2010
omalizumab	mab	Therapeutic	IgG	Human	IgE	1	Approved	2000
omburtamab	mab	Therapeutic	IgG	Mouse	CD276	1	Regulatory review	2018
omodembamab	mab	Therapeutic	IgG	Human	Staphylococcus aureus	1	Phase 1/2	2020
onartuzumab	mab	Therapeutic	Heterodimeric Fab-Fc	Human	HGFR	1	Phase 3	2010
onfekafusp	fusp	Therapeutic	scFv-protein fusion		Fibronectin	1	Phase 3	2017
ongerlicimab	mab	Therapeutic	IgG	Human	PCSK9	1	Phase 3	2019
ontamalimab	mab	Therapeutic	IgG	Human	MADCAM	1	Phase 3	2018
ontorpacept	cept	Therapeutic	Fc fusion protein (type 1)	Human	CD47	1	Phase 1/2	2019
ontuxizumab	mab	Therapeutic	IgG	Human	Endosialin	1	Phase 2	2013
onvatilimab	mab	Therapeutic	IgG	Human	VISTA	1	Phase 1	2017
opicinumab	mab	Therapeutic	IgG	Human	LINGO	1	Phase 2	2015
opinercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	TNF alpha	1	Phase 3	2017
oportuzumab	mab	Therapeutic	scFv-protein fusion		EpCAM	1	Regulatory review	2008
opucolimab	mab	Therapeutic	IgG	Human	PD-L1	1	Phase 1	2019
ordesekimab	mab	Therapeutic	IgG	Human	IL-15	1	Phase 2	2020
oregovomab	mab	Therapeutic	Unconfirmed		CA125	1	Phase 3	2002
orilanolimab	mab	Therapeutic	IgG	Human	FcRn	1	Phase 1/2	2018
ormutivimab	mab	Therapeutic	IgG	Human	Rabies virus	1	Approved	2021
orticumab	mab	Therapeutic	IgG	Human	Oxidized LDL	1	Phase 2	2012
osemitamab	mab	Therapeutic	IgG	Human	Claudin 18.2	1	Phase 2	2022
osocimab	mab	Therapeutic	IgG	Human	Factor XIa	1	Phase 2	2018
otelixizumab	mab	Therapeutic	IgG	Human	CD3	1	Phase 3	2008
otilimab	mab	Therapeutic	IgG	Human	GM-CSF	1	Phase 3	2018
otlertuzumab	mab	Therapeutic	scFv-Fc	Human	CD37	1	Phase 1/2	2013
oxelumab	mab	Therapeutic	IgG	Human	OX40L	1	Phase 2	2011
ozanezumab	mab	Therapeutic	IgG	Human	NOGO-A	1	Phase 2	2012
ozoralizumab	mab	Therapeutic	Triple dAb (type 2)		TNF alpha	2	Regulatory review	2011
ozurifitamab	mab	Therapeutic	IgG	Human	ROR2	1	Phase 2	2022
pabinafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	Transferrin receptor Heparin sulphate	2	Approved	2018
pacanalotamab	mab	Therapeutic	Tandem scFv		BCMA	2	Phase 1	2020
pacmilimab	mab	Therapeutic	Protease activated IgG	Human	PD-L1	1	Phase 2	2019
pagibaximab	mab	Therapeutic	Unconfirmed		Lipoteichoic acid	1	Phase 2/3	2005
palivizumab	mab	Therapeutic	Unconfirmed		Respiratory syncytial virus	1	Approved	1998
pamrevlumab	mab	Therapeutic	IgG	Human	CTGF	1	Phase 3	2015
panitumumab	mab	Therapeutic	IgG	Human	EGFR	1	Approved	2006
panobacumab	mab	Therapeutic	IgM	Human	Pseudomonas aeruginosa	1	Phase 2	2008
paridiprubart	bart	Therapeutic	IgG	Human	TLR4	1	Phase 2/3	2022
parsatuzumab	mab	Therapeutic	IgG	Human	EGFL7	1	Phase 2	2012
pascolizumab	mab	Therapeutic	IgG	Human	IL-4	1	Phase 2	2002
pasotuxizumab	mab	Therapeutic	Tandem scFv		PSMA	2	Phase 1	2014
pateclizumab	mab	Therapeutic	IgG	Human	Lymphotoxin	1	Phase 2	2011
patritumab	mab	Therapeutic	IgG	Human	HER3	1	Phase 3	2011
pavurutamab	mab	Therapeutic	Tandem scFv-scFc	Human	BCMA	2	Phase 1	2020
pelgifatamab	mab	Therapeutic	IgG	Human	PSMA	1	Phase 1	2022
pembrolizumab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2013
penpulimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2020
pepinemab	mab	Therapeutic	IgG	Human	SEMA4D	1	Phase 2	2018
perakizumab	mab	Therapeutic	IgG	Human	IL-17A	1	Phase 1	2012
peresolimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2022
pertuzumab	mab	Therapeutic	IgG	Human	HER2	1	Approved	2003
petosemtamab	mab	Therapeutic	Bispecific IgG (type 2)	Human	EGFR	2	Phase 1	2019
pexelizumab	mab	Therapeutic	scFv		C5	1	Phase 3	2002
pidilizumab	mab	Therapeutic	IgG	Human	DLL1	1	Phase 2	2012
pimivalimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2020
pimurutamab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 2	2019
pinatuzumab	mab	Therapeutic	IgG	Human	CD22	1	Phase 2	2012
pintumomab	mab	Therapeutic	Unconfirmed		Adenocarcinoma	1	Unknown	2002

pivekimab	mab	Therapeutic	IgG	Human	IL-3R	1	Phase 2	2021
placulumab	mab	Therapeutic	dAb-Fc	Human	TNF alpha	1	Phase 1/2	2012
plamotamab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	CD20 CD3	2	Phase 2	2018
plonmarlimab	mab	Therapeutic	IgG	Human	GM-CSF	1	Phase 2/3	2020
plozalizumab	mab	Therapeutic	IgG	Human	CCR2	1	Phase 2	2015
plutavimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Phase 2	2022
polatuzumab	mab	Therapeutic	IgG	Human	CD79b	1	Approved	2012
ponezumab	mab	Therapeutic	IgG	Human	Amyloid beta	1	Phase 2	2010
ponsegromab	mab	Therapeutic	IgG	Human	Growth Differ	1	Phase 1	2020
porgaviximab	mab	Therapeutic	IgG	Human	Ebola virus	1	Approved	2016
posdinemab	mab	Therapeutic	IgG	Human	Tau	1	Phase 2	2022
pozelimab	mab	Therapeutic	IgG	Human	C5	1	Phase 3	2018
praluzatamab	mab	Therapeutic	Protease activated IgG	Human	CD166	1	Phase 2	2019
prasinezumab	mab	Therapeutic	IgG	Human	Synuclein alpl	1	Phase 2	2017
prezalumab	mab	Therapeutic	IgG	Human	CD28	1	Phase 2	2015
priliximab	mab	Therapeutic	Unconfirmed		CD4	1	Phase 2	1998
pritoxaximab	mab	Therapeutic	IgG	Human	Shiga-like tox	1	Phase 2	2012
primumab	mab	Therapeutic	IgG	Human	Vimentin	1	Phase 2	2003
progolimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2018
pucotenlimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 3	2020
pulocimab	mab	Therapeutic	IgG	Human	VEGF-R2	1	Phase 1/2	2021
quavonlimab	mab	Therapeutic	IgG	Human	CTLA-4	1	Phase 3	2019
quetmolimab	mab	Therapeutic	IgG	Human	Fractalkine	1	Phase 2	2018
quilizumab	mab	Therapeutic	IgG	Human	IgE	1	Phase 2	2011
quisovalimab	mab	Therapeutic	IgG	Human	LIGHT	1	Phase 2	2021
racotumomab	mab	Therapeutic	IgG	Mouse	GM3	1	Approved	2008
radretumab	mab	Therapeutic	scFv-protein fusion		Fibronectin	1	Phase 2	2010
rafivirumab	mab	Therapeutic	IgG	Human	Rabies virus	1	Phase 2	2008
ragifilimab	mab	Therapeutic	IgG	Human	GITR	1	Phase 2	2019
ralpancizumab	mab	Therapeutic	IgG	Human	PCSK9	1	Phase 1	2013
ramatercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	ActRIIA liganc	1	Phase 2	2012
ramucirumab	mab	Therapeutic	IgG	Human	VEGF-R2	1	Approved	2013
ranevetmab	vetmab	Veterinary	IgG	Dog	NGF (canine)	1	Unknown	2020
ranibizumab	mab	Therapeutic	Fab	Human	VEGF	1	Approved	2004
ravagalimab	mab	Therapeutic	IgG	Human	CD40	1	Phase 2	2017
ravulizumab	mab	Therapeutic	IgG	Human	C5	1	Approved	2017
raxibacumab	mab	Therapeutic	Unconfirmed		Bacillus anthr	1	Approved	2004
recaticimab	mab	Therapeutic	IgG	Human	PCSK9	1	Phase 3	2020
refanezumab	mab	Therapeutic	IgG	Human	Myelin associ	1	Phase 2	2015
regavirumab	mab	Therapeutic	Unconfirmed		Herpes virus	1	Phase 1	1998
regdanvimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2020
relatlimab	mab	Therapeutic	IgG	Human	LAG-3	1	Approved	2018
relfovetmab	vetmab	Veterinary	IgG	Cat	NGF (feline)	1	Unknown	2018
remtolumab	mab	Therapeutic	Fv-IgG	Human	TNF alpha IL-17	2	Phase 2	2016
reozalimab	mab	Therapeutic	Bispecific IgG (type 4)	Human	PD-1 PD-L1	2	Phase 1/2	2022
reslizumab	mab	Therapeutic	Unconfirmed		IL-5	1	Approved	2001
retifanlimab	mab	Therapeutic	IgG	Human	PD-1	1	Regulatory review	2019
retlirafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	PD-L1 TGF beta	2	Phase 3	2020
revodofilimab	mab	Therapeutic	IgG	Human	OX40	1	Phase 1	2019
rlonacept	cept	Therapeutic	Fc fusion protein (type 2)	Human	IL-1 alpha IL-1 alpha	2	Approved	2006
rilotumumab	mab	Therapeutic	IgG	Human	HGF	1	Phase 3	2009
rinteravimab	mab	Therapeutic	dAb-Fc	Human	SARS-CoV-2	1	Phase 1	2021
rinucumab	mab	Therapeutic	IgG	Human	PDGF beta	1	Phase 2	2015
ripertamab	mab	Therapeutic	IgG	Human	CD20	1	Regulatory review	2019
risankizumab	mab	Therapeutic	IgG	Human	IL-23	1	Approved	2015
rituximab	mab	Therapeutic	IgG	Human	CD20	1	Approved	1997
rivabazumab	mab	Therapeutic	Fab	Human	Pseudomona:	1	Phase 2	2015
robatumumab	mab	Therapeutic	IgG	Human	IGF1R	1	Phase 2	2008
rocatinlimab	mab	Therapeutic	IgG	Human	OX40	1	Phase 3	2021
roledumab	mab	Therapeutic	IgG	Human	Rhesus D	1	Phase 2/3	2010
rolinsatamab	mab	Therapeutic	IgG	Human	Prolactin rece	1	Phase 1	2018
romilkimab	mab	Therapeutic	Fv-IgG	Human	IL-4 IL-13	2	Phase 2	2017
romlusevimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2021
romosozumab	mab	Therapeutic	IgG	Human	Sclerostin	1	Approved	2011
rontalizumab	mab	Therapeutic	IgG	Human	Interferon alp	1	Phase 2	2009
rosmantuzumab	mab	Therapeutic	IgG	Human	RSPO3	1	Phase 1	2016
rosnilimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2022
rosopatamab	mab	Therapeutic	IgG	Human	PSMA	1	Phase 3	2019
rovalpituzumab	mab	Therapeutic	IgG	Human	DLL3	1	Phase 3	2015
rovelizumab	mab	Therapeutic	IgG	Human	CD18	1	Phase 3	1999
rozanolixizumab	mab	Therapeutic	IgG	Human	FcRn	1	Phase 3	2016
rozibafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	BAFF ICOSL	2	Phase 2	2018
rulonilimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 2	2021
runimotamab	mab	Therapeutic	Bispecific IgG (type 1)	Human	HER2 CD3	2	Phase 1	2020
ruplizumab	mab	Therapeutic	IgG	Human	CD40L	1	Phase 2	2000
sabatolimab	mab	Therapeutic	IgG	Human	TIM-3	1	Phase 3	2019
sacituzumab	mab	Therapeutic	IgG	Human	TROP-2	1	Approved	2016
samalizumab	mab	Therapeutic	IgG	Human	CD200	1	Phase 1/2	2011
samrotamab	mab	Therapeutic	IgG	Human	LRRCL15	1	Phase 1	2017
sarilumab	mab	Therapeutic	IgG	Human	IL-6R	1	Approved	2011
sasanlimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 3	2019
satralizumab	mab	Therapeutic	IgG	Human	IL-6R	1	Approved	2016
satumomab	mab	Imaging	IgG	Human	Tag-72	1	Approved	1999
secukinumab	mab	Therapeutic	IgG	Human	IL-17A	1	Approved	2009
selicrelumab	mab	Therapeutic	IgG	Human	CD40	1	Phase 1	2016
semorinemab	mab	Therapeutic	IgG	Human	Tau	1	Phase 2	2018
semzuvolimab	mab	Therapeutic	IgG	Human	CD4	1	Phase 3	2022
serclutamab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 1	2018
seribantumab	mab	Therapeutic	IgG	Human	HER3	1	Phase 2	2012

serplulimab	mab	Therapeutic	IgG	Human	PD-1		1	Approved	2019
setoxaximab	mab	Therapeutic	IgG	Human	Shiga-like tox		1	Phase 2	2012
setrusumab	mab	Therapeutic	IgG	Human	Sclerostin		1	Phase 2/3	2017
sevirumab	mab	Therapeutic	Unconfirmed		CMV		1	Phase 2/3	1991
sibeprenlimab	mab	Therapeutic	IgG	Human	APRIL		1	Phase 3	2020
sibrotuzumab	mab	Therapeutic	Unconfirmed		FAP		1	Phase 2	2002
sifalimumab	mab	Therapeutic	IgG	Human	Interferon alfa		1	Phase 2	2010
siltuximab	mab	Therapeutic	IgG	Human	IL-6		1	Approved	2008
simlukafusp	fusp	Therapeutic	IgG-protein fusion (type 2)	Human	FAP	IL-2R	2	Phase 2	2019
simridarlimab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	PD-L1	CD47	2	Phase 1	2021
simtuzumab	mab	Therapeutic	IgG	Human	LOXL2		1	Phase 2	2012
sintilimab	mab	Therapeutic	IgG	Human	PD-1		1	Approved	2018
siplizumab	mab	Therapeutic	Unconfirmed		CD2		1	Phase 2	2002
sirexatamab	mab	Therapeutic	IgG	Human	DKK1		1	Phase 2	2021
sirtratumab	mab	Therapeutic	IgG	Human	SLITRK6		1	Phase 1	2017
sirukumab	mab	Therapeutic	IgG	Human	IL-6		1	Regulatory review	2011
socazolimab	mab	Therapeutic	IgG	Human	PD-L1		1	Regulatory review	2021
sofituzumab	mab	Therapeutic	IgG	Human	MUC16		1	Phase 1	2013
solanezumab	mab	Therapeutic	IgG	Human	Amyloid beta		1	Phase 3	2012
soltomab	mab	Therapeutic	Tandem scFv		EpCAM	CD3	2	Phase 1	2011
sonelokimab	mab	Therapeutic	Triple dAb (type 3)		IL-17A	IL-17F	3	Phase 2	2019
sonutzumab	mab	Therapeutic	Unconfirmed		MUC1		1	Phase 1	2005
sotatercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	ActRIIA ligand		1	Phase 3	2010
sotevtamab	mab	Therapeutic	IgG	Human	Clusterin		1	Phase 2	2021
sotigalimab	mab	Therapeutic	IgG	Human	CD40		1	Phase 2	2020
sotrovimab	mab	Therapeutic	IgG	Human	SARS-CoV-2		1	Approved	2020
sozinibercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	VEGF-R3		1	Unknown	2022
spartalizumab	mab	Therapeutic	IgG	Human	PD-1		1	Phase 2	2017
spesolimab	mab	Therapeutic	IgG	Human	IL-36R		1	Regulatory review	2018
stamulumab	mab	Therapeutic	IgG	Human	Myostatin		1	Phase 1/2	2006
suciraslimab	mab	Therapeutic	IgG	Human	CD22		1	Phase 3	2021
sudubrilimab	mab	Therapeutic	IgG	Human	PD-1		1	Phase 2	2020
sugemalimab	mab	Therapeutic	IgG	Human	PD-L1		1	Approved	2019
sulesomab	mab	Imaging	Unconfirmed		NCA-90		1	Approved	2002
suptavumab	mab	Therapeutic	IgG	Human	Respiratory syncytial virus		1	Phase 3	2016
surzebiclimab	mab	Therapeutic	IgG	Human	TIM-3		1	Phase 1/2	2020
sutimlimab	mab	Therapeutic	IgG	Human	C1s		1	Approved	2017
suvizumab	mab	Therapeutic	IgG	Human	HIV gp120		1	Phase 1	2009
svratoxumab	mab	Therapeutic	IgG	Human	Staphylococcus aureus		1	Phase 3	2016
tabalumab	mab	Therapeutic	IgG	Human	BLyS		1	Phase 3	2011
tabituximab	mab	Therapeutic	IgG	Human	Frizzled homolog		1	Phase 1	2018
tacatuzumab	mab	Therapeutic	IgG	Human	Alpha fetoprotein		1	Phase 1	2005
tadocizumab	mab	Therapeutic	Fab	Human	Integrin alpha5		1	Phase 2	2005
tafasitamab	mab	Therapeutic	IgG	Human	CD19		1	Approved	2018
tafolecimab	mab	Therapeutic	IgG	Human	PCSK9		1	Phase 3	2019
tagitanlimab	mab	Therapeutic	IgG	Human	PD-L1		1	Phase 3	2021
talacotuzumab	mab	Therapeutic	IgG	Human	IL-3R		1	Phase 2/3	2017
talizumab	mab	Therapeutic	IgG	Human	IgE		1	Phase 2	2003
talquetamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	GPCR5D	CD3	2	Phase 2	2019
tamgiblimab	mab	Therapeutic	IgG	Human	TIGIT		1	Phase 1	2021
tamrintamab	mab	Therapeutic	IgG	Human	DPEP3		1	Phase 1	2018
tamtuvetmab	vetmab	Veterinary	IgG	Dog	CD52		1	Unknown	2020
tanezumab	mab	Therapeutic	IgG	Human	NGF		1	Regulatory review	2008
taplitumomab	mab	Therapeutic	Unconfirmed		CD19		1	Unknown	2000
tarcochimab	mab	Therapeutic	IgG	Human	VEGF		1	Phase 3	2021
tarextumab	mab	Therapeutic	IgG	Human	Notch-2/Notch		1	Phase 2	2013
tarlatamab	mab	Therapeutic	Tandem scFv-scFc	Human	DLL3	CD3	2	Phase 2	2020
tavolimab	mab	Therapeutic	IgG	Human	OX40		1	Phase 1	2017
tebentafusp	fusp	Therapeutic	scFv-TCR fusion		gp100	CD3	2	Approved	2017
tebotelimab	mab	Therapeutic	Diabody-Fc (type 1)	Human	PD-1	LAG-3	2	Phase 2/3	2019
tecaginlimab	mab	Therapeutic	Bispecific IgG (type 6)	Human	CD40	4-1BB	2	Phase 1/2	2021
teclistamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	BCMA	CD3	2	Regulatory review	2018
tefibazumab	mab	Therapeutic	Unconfirmed		Staphylococcus aureus		1	Phase 2	2004
telazorlimab	mab	Therapeutic	IgG	Human	OX40		1	Phase 2	2019
telimomab	mab	Therapeutic	Unconfirmed		CD5		1	Unknown	1991
telisotuzumab	mab	Therapeutic	IgG	Human	HGFR		1	Phase 3	2016
telitacicept	cept	Therapeutic	Fc fusion protein (type 1)	Human	BLyS/APRIL		1	Phase 3	2018
temelimab	mab	Therapeutic	IgG	Human	HERV		1	Phase 2	2018
tenatumomab	mab	Therapeutic	IgG	Mouse	Tenascin-C		1	Phase 1	2008
teneliximab	mab	Therapeutic	IgG	Human	CD40		1	Phase 2	2002
teplizumab	mab	Therapeutic	IgG	Human	CD3		1	Regulatory review	2007
tepoditamab	mab	Therapeutic	Bispecific IgG (type 2)	Human	CLEC12A	CD3	2	Phase 1	2017
teprotumumab	mab	Therapeutic	IgG	Human	IGF1R		1	Approved	2009
teropavimab	mab	Therapeutic	IgG	Human	HIV gp120		1	Phase 2	2021
tesidolumab	mab	Therapeutic	IgG	Human	C5		1	Phase 2	2014
tesnatilimab	mab	Therapeutic	IgG	Human	CD314		1	Phase 2	2019
tezepelumab	mab	Therapeutic	IgG	Human	Thymic stroma		1	Approved	2015
tibulizumab	mab	Therapeutic	IgG-scFv (type 1)	Human	BAFF	IL-17A	2	Phase 2	2017
tidutamab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	SSTR2	CD3	2	Phase 1/2	2018
tifcemalimab	mab	Therapeutic	IgG	Human	BTLA		1	Phase 1/2	2020
tigatuzumab	mab	Therapeutic	IgG	Human	TRAIL-R2		1	Phase 2	2007
tilavonemab	mab	Therapeutic	IgG	Human	Tau		1	Phase 2	2018
tildrakizumab	mab	Therapeutic	IgG	Human	IL-23		1	Approved	2012
tilogotamab	mab	Therapeutic	IgG	Human	DR5		1	Phase 1/2	2019
tilvestamab	mab	Therapeutic	IgG	Human	AXL		1	Phase 1	2019
timigutuzumab	mab	Therapeutic	IgG	Human	HER2		1	Phase 1	2017
timolumab	mab	Therapeutic	IgG	Human	Vascular endothelial growth factor		1	Phase 2	2015
tinurilimab	mab	Therapeutic	IgG	Human	CEACAM6		1	Phase 1	2019
tiragolumab	mab	Therapeutic	IgG	Human	TIGIT		1	Phase 3	2017

tirnovetmab	vetmab	Veterinary	IgG	Dog	IL-31 (canine)	1	Unknown	2020
tislelizumab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2017
tisotumab	mab	Therapeutic	IgG	Human	Thromboplas	1	Approved	2015
tixagevimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Approved	2020
tocilizumab	mab	Therapeutic	IgG	Human	IL-6R	1	Approved	2004
tomaralimab	mab	Therapeutic	IgG	Human	TLR2	1	Phase 2	2018
tomuzotuximab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 2	2017
toralizumab	mab	Therapeutic	Unconfirmed		CD40L	1	Phase 2	2002
toripalimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2018
torudokimab	mab	Therapeutic	IgG	Human	IL-33	1	Phase 2	2020
tosatoxumab	mab	Therapeutic	IgG	Human	Staphylococci	1	Phase 3	2013
tositumomab	mab	Therapeutic	Unconfirmed		CD20	1	Approved (withdra	1998
tovetumab	mab	Therapeutic	IgG	Human	PDGF alpha	1	Phase 2	2013
tozorakimab	mab	Therapeutic	IgG	Human	IL-33	1	Phase 3	2020
tralokinumab	mab	Therapeutic	IgG	Human	IL-13	1	Approved	2009
trastuzumab	mab	Therapeutic	IgG	Human	HER2	1	Approved	1997
trebananib	Other	Therapeutic	Fc fusion protein (type 6)	Human	Ang-1/Ang-2	1	Phase 3	2011
tregalizumab	mab	Therapeutic	IgG	Human	CD4	1	Phase 2	2010
tremelimumab	mab	Therapeutic	IgG	Human	CTLA-4	1	Regulatory review	2007
trevogrumab	mab	Therapeutic	IgG	Human	Myostatin	1	Phase 2	2015
trinbelimab	mab	Therapeutic	IgG	Human	Rhesus D	1	Approved	2021
trontinemab	mab	Therapeutic	Fab-IgG (type 3)	Human	Amyloid beta Transferrin re	2	Phase 1/2	2022
tucotuzumab	mab	Therapeutic	IgG-protein fusion (type 1)	Human	EpCAM IL-2R	2	Phase 2	2006
tulinercept	cept	Therapeutic	Fc fusion protein (type 1)	Human	TNF alpha	1	Phase 2	2016
tusamitamab	mab	Therapeutic	IgG	Human	CEACAM5	1	Phase 3	2020
tuvirumab	mab	Therapeutic	Unconfirmed		Hepatitis B vir	1	Phase 2	1991
tuvonralimab	mab	Therapeutic	IgG	Human	CTLA-4	1	Phase 2	2021
ubamatamab	mab	Therapeutic	Bispecific IgG (type 3)	Human	MUC16 CD3	2	Phase 1/2	2021
ublituximab	mab	Therapeutic	IgG	Human	CD20	1	Regulatory review	2010
ulenistamab	mab	Therapeutic	IgG	Human	PAUF	1	Phase 1/2	2021
uliledlimab	mab	Therapeutic	IgG	Human	CD73	1	Phase 1/2	2020
ulocuplumab	mab	Therapeutic	IgG	Human	CXCR4	1	Phase 1/2	2013
unasnemab	mab	Therapeutic	IgG	Human	Repulsive Gui	1	Phase 2	2020
upanovimab	mab	Therapeutic	IgG	Human	SARS-CoV-2	1	Phase 2/3	2021
upifitamab	mab	Therapeutic	IgG	Human	NaPi2b	1	Phase 3	2019
urabrelimab	mab	Therapeutic	IgG	Human	CD47	1	Phase 1	2019
urelumab	mab	Therapeutic	IgG	Human	4-1BB	1	Phase 2	2010
urtoxazumab	mab	Therapeutic	IgG	Human	Shiga-like tox	1	Phase 2	2004
ustekinumab	mab	Therapeutic	IgG	Human	IL-12/IL-23	1	Approved	2008
utomilumab	mab	Therapeutic	IgG	Human	4-1BB	1	Phase 3	2016
vadastuximab	mab	Therapeutic	IgG	Human	CD33	1	Phase 3	2015
valanafusp	fusp	Therapeutic	IgG-protein fusion (type 1)	Human	Insulin recept Glycosaminog	2	Phase 2	2017
vandortuzumab	mab	Therapeutic	IgG	Human	STEAP1	1	Phase 1	2014
vantictumab	mab	Therapeutic	IgG	Human	Frizzled homc	1	Phase 1	2013
vanucizumab	mab	Therapeutic	Bispecific IgG (type 5)	Human	Ang-2 VEGF	2	Phase 2	2015
vapaliximab	mab	Therapeutic	Unconfirmed		Vascular adhe	1	Phase 1	2002
varisacumab	mab	Therapeutic	IgG	Human	VEGF	1	Phase 1	2016
varlilumab	mab	Therapeutic	IgG	Human	CD27	1	Phase 2	2014
vatelizumab	mab	Therapeutic	IgG	Human	Integrin alph	1	Phase 2	2011
vedolizumab	mab	Therapeutic	IgG	Human	Integrin alph	1	Approved	2008
veltuzumab	mab	Therapeutic	IgG	Human	CD20	1	Phase 1/2	2007
vepalimomab	mab	Therapeutic	Unconfirmed		Vascular adhe	1	Phase 1	1998
vepsitamab	mab	Therapeutic	Tandem scFv-scFc	Human	MUC17 CD3	2	Phase 1	2021
vesencumab	mab	Therapeutic	IgG	Human	Neuropilin 1	1	Phase 1	2010
vibecotamab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	CD123 CD3	2	Phase 1	2018
vibostolimab	mab	Therapeutic	IgG	Human	TIGIT	1	Phase 3	2019
vilobelimab	mab	Therapeutic	IgG	Human	CS	1	Phase 3	2019
visilizumab	mab	Therapeutic	IgG	Human	CD3	1	Phase 3	2000
visugromab	mab	Therapeutic	IgG	Human	GDF15	1	Phase 2	2022
vixarelimab	mab	Therapeutic	IgG	Human	Oncostatin M	1	Phase 2	2020
vixtimotamab	mab	Therapeutic	Tandem scFv		CD33 CD3	2	Phase 1	2020
vobarilizumab	mab	Therapeutic	Tandem dAb (type 2)		IL-6R albumin	2	Phase 2	2015
vobramitamab	mab	Therapeutic	IgG	Human	B7-H3	1	Phase 1/2	2022
vofatamab	mab	Therapeutic	IgG	Human	FGFR3	1	Phase 1/2	2018
volagidemab	mab	Therapeutic	IgG	Human	GCGR	1	Phase 2	2018
volociximab	mab	Therapeutic	IgG	Human	Integrin alph	1	Phase 2	2005
vonlerolizumab	mab	Therapeutic	IgG	Human	OX40	1	Phase 2	2016
vopratelimab	mab	Therapeutic	IgG	Human	CD278	1	Phase 2	2017
vorsetuzumab	mab	Therapeutic	IgG	Human	CD70	1	Phase 1	2012
votumumab	mab	Imaging	Unconfirmed		CTAA16.88	1	Approved (withdra	1998
voxalatamab	mab	Therapeutic	Bispecific IgG (type 6)	Human	PSMA CD3	2	Phase 1	2021
vudalimab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	PD-1 CTLA4	2	Phase 2	2020
vulinacimab	mab	Therapeutic	IgG	Human	VEGF-R2	1	Phase 1	2019
vunakizumab	mab	Therapeutic	IgG	Human	IL-17A	1	Phase 2/3	2016
xeligekimab	mab	Therapeutic	IgG	Human	IL-17A	1	Phase 3	2021
xentuzumab	mab	Therapeutic	IgG	Human	IGF1/IGF2	1	Phase 2	2015
zagotenemab	mab	Therapeutic	IgG	Human	Tau	1	Phase 2	2021
zalifrelimab	mab	Therapeutic	IgG	Human	CTLA-4	1	Phase 2	2019
zalutumumab	mab	Therapeutic	IgG	Human	EGFR	1	Phase 3	2005
zamerovimab	mab	Therapeutic	IgG	Human	Rabies virus	1	Phase 3	2021
zampilimab	mab	Therapeutic	IgG	Human	Transglutamin	1	Phase 1/2	2018
zanidatamab	mab	Therapeutic	Heterodimeric Fab/scFv-Fc	Human	HER2 HER2	2	Phase 3	2019
zanolimumab	mab	Therapeutic	Unconfirmed		CD4	1	Phase 3	2004
zansecimab	mab	Therapeutic	IgG	Human	Ang-2	1	Phase 2	2020
zelminemab	mab	Therapeutic	IgG	Human	PAC1 recepto	1	Phase 2	2019
zeluvalimab	mab	Therapeutic	IgG	Human	PD-1	1	Phase 1	2020
zenocutuzumab	mab	Therapeutic	Bispecific IgG (type 2)	Human	HER2 HER3	2	Phase 2	2017
zilovertamab	mab	Therapeutic	IgG	Human	ROR1	1	Phase 3	2020
ziltivekimab	mab	Therapeutic	IgG	Human	IL-6	1	Phase 3	2019

zimberelimab	mab	Therapeutic	IgG	Human	PD-1	1	Approved	2020
zinlirvimab	mab	Therapeutic	IgG	Human	HIV gp120	1	Phase 1	2022
ziralimumab	mab	Therapeutic	Unconfirmed		CD147	1	Phase 1	2000
zolbetuximab	mab	Therapeutic	IgG	Human	Claudin 18.2	1	Phase 3	2017
zolimomab	mab	Therapeutic	Unconfirmed		CD5	1	Unknown	1998
zuberitamab	mab	Therapeutic	IgG	Human	CD20	1	Phase 3	2019